A previously healthy 36-year-old male was evaluated in the emergency department with two weeks of left-sided abdominal pain and diarrhea. The pain radiated to his back and was associated with poor oral intake and a 25-pound weight loss. Bowel movements numbered 4–5 per day, with urgency and intermittent bleeding. Initial evaluation revealed a normal complete blood count and liver function tests, although lipase 722 U/L (ULN = 90 U/L), CRP 3.5 mg/dL and calprotectin 750 µg/g were elevated. Stool tests were negative for infection (Clostridioides difficile, ova/parasites, Giardia, and bacteria). A CT scan demonstrated peripancreatic fat stranding (Image 1); a right upper quadrant ultrasound was negative for gallstones or biliary dilation (common bile duct = 3 mm). Serum calcium was normal (9.3 mg/dL) as were non-fasting triglycerides (97 mg/dL). He denied alcohol use, recent travel, sick contacts, as well as family history of pancreatitis or inflammatory bowel disease. Genetic testing was negative for cystic fibrosis transmembrane regulator (CFTR), chymotrypsin C (CTRC), human cationic trypsinogen (PRSS)1, and serine protease inhibitor, Kazal-type (SPINK)1 mutations. IgG subclasses showed a normal serum IgG4 level (82.5 mg/dL).
WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.